Mekinist Euroopan unioni - tanska - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.

Seroxat 30 mg filmovertrukne tabletter Tanska - tanska - Lægemiddelstyrelsen (Danish Medicines Agency)

seroxat 30 mg filmovertrukne tabletter

glaxosmithkline pharma a/s - paroxetinhydrochloridhemihydrat - filmovertrukne tabletter - 30 mg

Seroxat 30 mg filmovertrukne tabletter Tanska - tanska - Lægemiddelstyrelsen (Danish Medicines Agency)

seroxat 30 mg filmovertrukne tabletter

paranova danmark a/s - paroxetinhydrochloridhemihydrat - filmovertrukne tabletter - 30 mg